BRPI0417309A - proteìna nmb1125 e seu uso em formulações farmacêuticas - Google Patents
proteìna nmb1125 e seu uso em formulações farmacêuticasInfo
- Publication number
- BRPI0417309A BRPI0417309A BRPI0417309-0A BRPI0417309A BRPI0417309A BR PI0417309 A BRPI0417309 A BR PI0417309A BR PI0417309 A BRPI0417309 A BR PI0417309A BR PI0417309 A BRPI0417309 A BR PI0417309A
- Authority
- BR
- Brazil
- Prior art keywords
- formulations
- nmb1125
- protein
- nmb1125 protein
- diseases
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title abstract 6
- 102000004169 proteins and genes Human genes 0.000 title abstract 4
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 238000009472 formulation Methods 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 3
- 229960005486 vaccine Drugs 0.000 abstract 3
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 241000588650 Neisseria meningitidis Species 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 238000010171 animal model Methods 0.000 abstract 1
- 230000000844 anti-bacterial effect Effects 0.000 abstract 1
- 230000001580 bacterial effect Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000005847 immunogenicity Effects 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 239000012528 membrane Substances 0.000 abstract 1
- 244000052769 pathogen Species 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 230000003449 preventive effect Effects 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 230000001681 protective effect Effects 0.000 abstract 1
- 238000001228 spectrum Methods 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
"PROTEìNA NMB1125 E SEU USO EM FORMULAçõES FARMACêUTICAS". A presente invenção refere-se ao uso de um novo antígeno para vacina aplicado em um modo preventivo ou terapêutico contra doenças em geral, sendo essas doenças de origem bacteriana, viral, câncer correlato, ou outras origens. O objetivo técnico que esta invenção prossegue é o desenvolvimento de formulações com a capacidade de aumentar o espectro protetor de vacinas existentes e, portanto, expandindo-o contra diferentes patógenos. A fim de atingir esse objetivo a proteína NMB1125 foi isolada e identificada como um componente de preparações de membranas externas de Neisseria meningitidis capaz de induzir atividade bactericida. Adicionalmente, o gene que codifica a proteína NMB1125 foi clonado e expresso, e o polipeptídeo foi purificado e sua imunogenicidade avaliada em modelos animais. Os dados de seqüência de genes homólogos mostraram, devido ao alto grau de conservação, seu alto valor como um antígeno alvo de uma resposta reativa de forma cruzada quando ele é apresentado por vias diferentes. Formulações resultantes desta invenção são de uso na indústria farmacêutica como formulações de vacina para uso humano.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CU20030285A CU23237A1 (es) | 2003-12-03 | 2003-12-03 | PROTEINA NMB1125 Y SU USO EN FORMULACIONES FARMACéUTICAS |
| PCT/CU2004/000015 WO2005054281A2 (es) | 2003-12-03 | 2004-12-02 | Proteína nmb1125 y su uso en formulaciones farmaceuticas |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0417309A true BRPI0417309A (pt) | 2007-09-11 |
Family
ID=40091628
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0417309-0A BRPI0417309A (pt) | 2003-12-03 | 2004-12-02 | proteìna nmb1125 e seu uso em formulações farmacêuticas |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US7691971B2 (pt) |
| EP (1) | EP1693378B9 (pt) |
| KR (1) | KR20060123759A (pt) |
| CN (1) | CN1890260A (pt) |
| AR (1) | AR047263A1 (pt) |
| AT (1) | ATE444305T1 (pt) |
| AU (1) | AU2004294376A1 (pt) |
| BR (1) | BRPI0417309A (pt) |
| CA (1) | CA2547317A1 (pt) |
| CU (1) | CU23237A1 (pt) |
| DE (1) | DE602004023419D1 (pt) |
| ES (1) | ES2334138T3 (pt) |
| NO (1) | NO20063020L (pt) |
| NZ (1) | NZ547520A (pt) |
| PL (1) | PL1693378T3 (pt) |
| RU (1) | RU2336900C2 (pt) |
| WO (1) | WO2005054281A2 (pt) |
| ZA (1) | ZA200604556B (pt) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CU22559A1 (es) * | 1996-01-17 | 1999-05-03 | Ct Ingenieria Genetica Biotech | Sistema de expresión de antígenos heterologos en e. coli como proteínas de fusión |
| EP2261347A3 (en) * | 1998-05-01 | 2012-01-11 | Novartis Vaccines and Diagnostics, Inc. | Neisseria meningitidis antigens and compositions |
| AU780308B2 (en) | 1999-04-30 | 2005-03-17 | J. Craig Venter Institute, Inc. | Neisseria genomic sequences and methods of their use |
-
2003
- 2003-12-03 CU CU20030285A patent/CU23237A1/es unknown
-
2004
- 2004-12-01 AR ARP040104481A patent/AR047263A1/es unknown
- 2004-12-02 CN CNA2004800358779A patent/CN1890260A/zh active Pending
- 2004-12-02 WO PCT/CU2004/000015 patent/WO2005054281A2/es active Application Filing
- 2004-12-02 NZ NZ547520A patent/NZ547520A/xx unknown
- 2004-12-02 DE DE602004023419T patent/DE602004023419D1/de active Active
- 2004-12-02 BR BRPI0417309-0A patent/BRPI0417309A/pt not_active IP Right Cessation
- 2004-12-02 RU RU2006123434/13A patent/RU2336900C2/ru not_active IP Right Cessation
- 2004-12-02 AT AT04802607T patent/ATE444305T1/de not_active IP Right Cessation
- 2004-12-02 AU AU2004294376A patent/AU2004294376A1/en not_active Abandoned
- 2004-12-02 PL PL04802607T patent/PL1693378T3/pl unknown
- 2004-12-02 CA CA002547317A patent/CA2547317A1/en not_active Abandoned
- 2004-12-02 US US10/580,508 patent/US7691971B2/en not_active Expired - Fee Related
- 2004-12-02 ES ES04802607T patent/ES2334138T3/es active Active
- 2004-12-02 KR KR1020067010712A patent/KR20060123759A/ko not_active Application Discontinuation
- 2004-12-02 EP EP04802607A patent/EP1693378B9/en active Active
-
2006
- 2006-06-02 ZA ZA200604556A patent/ZA200604556B/xx unknown
- 2006-06-28 NO NO20063020A patent/NO20063020L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2005054281A3 (es) | 2005-08-04 |
| AU2004294376A1 (en) | 2005-06-16 |
| PL1693378T3 (pl) | 2010-03-31 |
| DE602004023419D1 (de) | 2009-11-12 |
| EP1693378A2 (en) | 2006-08-23 |
| ATE444305T1 (de) | 2009-10-15 |
| ES2334138T3 (es) | 2010-03-05 |
| EP1693378B9 (en) | 2010-05-19 |
| NO20063020L (no) | 2006-09-01 |
| EP1693378B1 (en) | 2009-09-30 |
| CN1890260A (zh) | 2007-01-03 |
| RU2006123434A (ru) | 2008-01-10 |
| NZ547520A (en) | 2009-07-31 |
| US20070218000A1 (en) | 2007-09-20 |
| CU23237A1 (es) | 2007-09-26 |
| WO2005054281A2 (es) | 2005-06-16 |
| CA2547317A1 (en) | 2005-06-16 |
| KR20060123759A (ko) | 2006-12-04 |
| AR047263A1 (es) | 2006-01-11 |
| US7691971B2 (en) | 2010-04-06 |
| ZA200604556B (en) | 2007-03-28 |
| RU2336900C2 (ru) | 2008-10-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Pourseif et al. | Current status and future prospective of vaccine development against Echinococcus granulosus | |
| KR100615109B1 (ko) | 모렉셀라 카타르할리스의 ｕｓｐａ1, ｕｓｐａ2 항원 | |
| CN106132432A (zh) | 用于瘤形成疫苗的配制品 | |
| CN107250353B (zh) | 二价猪流感病毒疫苗 | |
| JP6632974B2 (ja) | フェノール可溶性モジュリン、δ毒素、スーパー抗原に由来するトキソイドペプチド、およびその融合物 | |
| ES2926543T3 (es) | Atenuación de la virulencia bacteriana mediante la atenuación del transporte de folato bacteriano | |
| UA113496C2 (xx) | Вектор і спосіб підвищення стійкості до інфекції, що викликається campylobacter | |
| McManus | A vaccine against Asian schistosomiasis: the story unfolds | |
| CN106794236A (zh) | A群链球菌疫苗 | |
| Mingxiao et al. | Immunogenicity of plasmids encoding P12A and 3C of FMDV and swine IL-18 | |
| Wolfenden et al. | Development and evaluation of candidate recombinant Salmonella-vectored Salmonella vaccines | |
| Soudi et al. | Evaluation of Helicobacter pylori OipA protein as a vaccine candidate and propolis as an adjuvant in C57BL/6 mice | |
| CN106535930A (zh) | 猪流行性腹泻病毒疫苗及其使用方法 | |
| BRPI0417334A (pt) | proteìna nmb0928 e uso da mesma em formulações farmacêuticas | |
| CN104271744A (zh) | 分枝杆菌感染的预防和治疗 | |
| JP2012509664A (ja) | スタフィロコッカス・アウレウス（ｓｔａｐｈｙｌｏｃｏｃｃｕｓａｕｒｅｕｓ）に対する防御免疫応答を誘導するポリペプチド | |
| BRPI0417309A (pt) | proteìna nmb1125 e seu uso em formulações farmacêuticas | |
| JP2012509665A (ja) | スタフィロコッカス・アウレウス（ｓｔａｐｈｙｌｏｃｏｃｃｕｓａｕｒｅｕｓ）に対する防御免疫応答を誘導するポリペプチド | |
| BR0208980A (pt) | Vacinas incluindo ifn do tipo i como um adjuvante e processos relacionados a esses | |
| Nuñez-Ortiz et al. | Immunostimulant properties of full-length and truncated Marinobacter algicola flagellins, and their effects against viral hemorrhagic septicemia virus (VHSV) in trout | |
| US20130122034A1 (en) | Staphylococcus aureus surface protein sa1789 and protective vaccine based thereon | |
| PT2256185E (pt) | Protecção heteróloga contra pasteurella multocida provida por células de p. multocida fur e seus extractos proteicos de membrana externa | |
| NO20084524L (no) | Farmasoytisk sammensetning inneholdende NMB0938-protein | |
| Malheiro et al. | pcDNA-IL-12 vaccination blocks eosinophilic inflammation but not airway hyperresponsiveness following murine Toxocara canis infection | |
| ES2363015T3 (es) | Secuencia de adn y preparación recombinante de alérgenos mayores del grupo 4 de cereales. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 6A E 7A ANUIDADE(S) |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2129 DE 25/10/2011. |